Clinical outcomes of patients treated with Dolutegravir functional monotherapy or Dolutegravir plus an active
non-cytosine nucleoside analog: a retrospective observational cohort study of treatment-experienced patients
IDWeek, October 2-6, 2019, Washington, DC
Reported by Jules Levin
Charlotte-Paige Rolle MD MPH1, 2; Beth Bryant CRC1;ColtonJ. Tucker BSc3;Maria CamilaCastro BA4; Vu Nguyen MS5; Federico HinestrosaMD1,5; Edwin DeJesusMD1,5
